Allarity Therapeutics Stock Price To Earnings To Growth

ALLR Stock

USD 1.10 0.01 0.90%

Allarity Therapeutics fundamentals help investors to digest information that contributes to Allarity Therapeutics' financial success or failures. It also enables traders to predict the movement of Allarity Stock. The fundamental analysis module provides a way to measure Allarity Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Allarity Therapeutics stock.

Total Current Liabilities Other Current Liab

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Allarity Therapeutics Company Price To Earnings To Growth Analysis

Allarity Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Allarity Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Allarity Therapeutics is extremely important. It helps to project a fair market value of Allarity Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Allarity Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Allarity Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Allarity Therapeutics' interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Intangible Assets	Long Term Debt	Current Deferred Revenue	Short Term Investments	Capital Surpluse	Deferred Long Term Liab
Net Tangible Assets		0.12	-0.71	-0.59	-0.21	-0.46	-0.34	-0.03	-0.04	0.0	0.02	-0.04	-0.05	0.0	-0.01	-0.01	0.0	-0.03	0.02	-0.03	-0.03	-0.01	-0.01
Retained Earnings	0.12		-0.54	0.28	0.13	0.68	0.43	0.58	0.91	0.02	-0.47	0.91	-0.36	-0.64	-0.77	0.84	-0.54	0.86	-0.91	0.91	0.91	0.77	0.77
Accounts Payable	-0.71	-0.54		0.53	-0.05	0.09	-0.22	-0.55	-0.48	0.35	-0.13	-0.47	0.0	0.02	0.23	-0.45	0.32	-0.48	0.42	-0.45	-0.45	-0.3	-0.3
Net Receivables	-0.59	0.28	0.53		0.46	0.81	-0.19	0.22	0.37	0.09	-0.29	0.36	-0.53	-0.55	-0.62	0.45	-0.43	0.42	-0.49	0.47	0.47	0.35	0.35
Total Current Assets	-0.21	0.13	-0.05	0.46		0.42	-0.35	0.72	0.39	-0.82	0.6	0.38	-0.38	0.13	-0.33	0.63	-0.58	0.42	-0.31	0.48	0.48	0.43	0.43
Common Stock	-0.46	0.68	0.09	0.81	0.42		0.2	0.56	0.81	-0.01	-0.38	0.81	-0.26	-0.58	-0.68	0.71	-0.54	0.8	-0.8	0.82	0.82	0.6	0.6
Property Plant Equipment	-0.34	0.43	-0.22	-0.19	-0.35	0.2		0.15	0.37	0.12	-0.29	0.38	0.31	-0.1	-0.03	0.14	0.03	0.3	-0.27	0.25	0.25	0.19	0.19
Total Assets	-0.03	0.58	-0.55	0.22	0.72	0.56	0.15		0.78	-0.72	0.36	0.77	-0.16	-0.1	-0.51	0.79	-0.74	0.85	-0.68	0.81	0.81	0.48	0.48
Total Stockholder Equity	-0.04	0.91	-0.48	0.37	0.39	0.81	0.37	0.78		-0.23	-0.25	1.0	-0.17	-0.44	-0.66	0.88	-0.58	0.94	-0.9	0.96	0.96	0.77	0.77
Net Debt	0.0	0.02	0.35	0.09	-0.82	-0.01	0.12	-0.72	-0.23		-0.88	-0.22	0.03	-0.45	0.0	-0.39	0.47	-0.26	0.03	-0.28	-0.28	-0.19	-0.19
Total Liab	0.02	-0.47	-0.13	-0.29	0.6	-0.38	-0.29	0.36	-0.25	-0.88		-0.27	0.1	0.67	0.33	-0.06	-0.18	-0.17	0.39	-0.19	-0.19	-0.23	-0.23
Net Invested Capital	-0.04	0.91	-0.47	0.36	0.38	0.81	0.38	0.77	1.0	-0.22	-0.27		-0.16	-0.42	-0.64	0.88	-0.54	0.92	-0.9	0.95	0.95	0.79	0.79
Long Term Investments	-0.05	-0.36	0.0	-0.53	-0.38	-0.26	0.31	-0.16	-0.17	0.03	0.1	-0.16		0.59	0.77	-0.52	0.56	-0.27	0.41	-0.41	-0.41	-0.39	-0.39
Short Long Term Debt	0.0	-0.64	0.02	-0.55	0.13	-0.58	-0.1	-0.1	-0.44	-0.45	0.67	-0.42	0.59		0.86	-0.38	0.57	-0.55	0.61	-0.58	-0.58	-0.26	-0.26
Capital Stock	-0.01	-0.77	0.23	-0.62	-0.33	-0.68	-0.03	-0.51	-0.66	0.0	0.33	-0.64	0.77	0.86		-0.75	0.81	-0.77	0.81	-0.83	-0.83	-0.51	-0.51
Net Working Capital	-0.01	0.84	-0.45	0.45	0.63	0.71	0.14	0.79	0.88	-0.39	-0.06	0.88	-0.52	-0.38	-0.75		-0.64	0.84	-0.88	0.92	0.92	0.86	0.86
Short Term Debt	0.0	-0.54	0.32	-0.43	-0.58	-0.54	0.03	-0.74	-0.58	0.47	-0.18	-0.54	0.56	0.57	0.81	-0.64		-0.76	0.57	-0.77	-0.77	-0.3	-0.3
Intangible Assets	-0.03	0.86	-0.48	0.42	0.42	0.8	0.3	0.85	0.94	-0.26	-0.17	0.92	-0.27	-0.55	-0.77	0.84	-0.76		-0.92	0.97	0.97	0.58	0.58
Long Term Debt	0.02	-0.91	0.42	-0.49	-0.31	-0.8	-0.27	-0.68	-0.9	0.03	0.39	-0.9	0.41	0.61	0.81	-0.88	0.57	-0.92		-0.92	-0.92	-0.67	-0.67
Current Deferred Revenue	-0.03	0.91	-0.45	0.47	0.48	0.82	0.25	0.81	0.96	-0.28	-0.19	0.95	-0.41	-0.58	-0.83	0.92	-0.77	0.97	-0.92		1.0	0.74	0.74
Short Term Investments	-0.03	0.91	-0.45	0.47	0.48	0.82	0.25	0.81	0.96	-0.28	-0.19	0.95	-0.41	-0.58	-0.83	0.92	-0.77	0.97	-0.92	1.0		0.74	0.74
Capital Surpluse	-0.01	0.77	-0.3	0.35	0.43	0.6	0.19	0.48	0.77	-0.19	-0.23	0.79	-0.39	-0.26	-0.51	0.86	-0.3	0.58	-0.67	0.74	0.74		1.0
Deferred Long Term Liab	-0.01	0.77	-0.3	0.35	0.43	0.6	0.19	0.48	0.77	-0.19	-0.23	0.79	-0.39	-0.26	-0.51	0.86	-0.3	0.58	-0.67	0.74	0.74	1.0

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Allarity Therapeutics

Allarity Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

580.77

At this time, Allarity Therapeutics' Price Earnings To Growth Ratio is relatively stable compared to the past year.

Based on the latest financial disclosure, Allarity Therapeutics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run Financial Widgets Now

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets

All Next

Launch Module

Allarity Fundamentals

	Return On Equity	-1.22
	Return On Asset	-0.48
	Current Valuation	(12.2 M)
	Shares Outstanding	1.41 M
	Shares Owned By Insiders	12.30 %
	Shares Owned By Institutions	1.20 %
	Number Of Shares Shorted	168.77 K
	Price To Book	0.38 X
	Gross Profit	(36.35 M)
	EBITDA	(12.08 M)
	Net Income	(11.9 M)
	Cash And Equivalents	7.73 M
	Cash Per Share	0.75 X
	Total Debt	1.3 M
	Debt To Equity	0.11 %
	Current Ratio	0.88 X
	Book Value Per Share	16.98 X
	Cash Flow From Operations	(12.74 M)
	Short Ratio	0.30 X
	Earnings Per Share	(10.98) X
	Target Price	5.0
	Beta	0.29
	Market Capitalization	2.06 M
	Total Asset	11.86 M
	Retained Earnings	(94.45 M)
	Working Capital	(12.2 M)
	Net Asset	11.86 M

About Allarity Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Allarity Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allarity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allarity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Allarity Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allarity Stock

0.68

ELAN

Elanco Animal Health

Pair Corr

Moving against Allarity Stock

0.88	BHC	Bausch Health Companies	Pair Corr
0.87	EWTX	Edgewise Therapeutics	Pair Corr
0.82	GILD	Gilead Sciences	Pair Corr
0.72	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.71	GANX	Gain Therapeutics	Pair Corr

The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.

The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Allarity Stock Analysis

When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC